How many Cochlear shares do I need to buy for $10,000 of passive income?

The dividend maths on this fallen ASX healthcare heavyweight.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Working out how many Cochlear Ltd (ASX: COH) shares you need for $10,000 of passive income is simple maths, but the answer might catch you off guard.

Cochlear is the world's leading maker of implantable hearing solutions, holding around 60% of the global cochlear implant market.

For years, the company was a dependable compounder that quietly rewarded patient shareholders.

The past 12 months, however, have tested even its most loyal investors.

An older woman tries to listen by cupping her ear.

Image source: Getty Images

The dividend maths for Cochlear shares

Cochlear pays two dividends to shareholders each year.

Lately, those payments have added up to an annual dividend of $4.30 per share.

The most recent interim dividend of $2.15 was franked at 85%, which adds a further tax benefit for many holders.

To generate $10,000 in annual passive income, including franking credits, the calculation is straightforward.

You simply divide $10,000 by the grossed-up dividend of about $5.87 (the $4.30 cash payout plus roughly $1.57 in franking credits).

That works out to roughly 1,705 Cochlear shares.

At current share prices of around $118, those shares would set you back close to $201,190.

That is a serious amount of capital for most everyday investors to commit, and it is also a reminder that Cochlear has never really been an income stock at heart.

At current prices, the shares offer a gross dividend yield of about 3.6%, although franking credits sweeten that headline return a little further at tax time.

Why have Cochlear shares fallen so far?

The dividend is only half the story here.

Cochlear shares have dropped heavily over the past year, one of the reasons why Cochlear's dividend yield looks unusually generous now.

The stock currently trades far below its 52-week high of $319.56, largely due to a run of disappointing news from the company itself.

Recent earnings in focus

Cochlear reported its half-year results for the six months to 31 December 2025 back in February.

In these results, sales revenue came in at about $1.17 billion, broadly flat on the prior corresponding period. Statutory net profit fell a nasty 21% to $161.5 million, and underlying net profit slipped 9% to $195 million.

The weaker result was driven largely by the costly rollout of the new Nexa implant system, while competitive discounting from rivals chipped away at market share.

Management chose to hold the interim dividend steady rather than lift it, a call that speaks volumes about the year ahead.

Investors will get their next major update when Cochlear reports its full-year FY26 results on 18 August 2026.

Are Cochlear shares worth it for the income?

That is the real question for income-focused investors.

Cochlear is a high-quality business with a wide competitive moat, but its dividend yield is modest next to the ASX banks or Telstra Group Ltd (ASX: TLS).

An investor chasing pure income could reach $10,000 with far less capital elsewhere.

The appeal of Cochlear shares has always been growth, not yield, and anyone buying today is really paying for a long-term recovery story.

In other words, the dividend is a bonus, not the main event.

Foolish Takeaway

You would need roughly 1,705 Cochlear shares to earn $10,000 in annual passive income once franking credits are included.

At current prices, that means an outlay of close to $201,000.

For most investors, Cochlear shares make more sense as a growth holding than a pure income one.

On the growth front, Cochlear's looming FY26 result will tell us whether the recovery is finally on track.

Until then, the passive income case remains an expensive one to make.

Motley Fool contributor Mark Verhoeven has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Cochlear. The Motley Fool Australia has positions in and has recommended Telstra Group. The Motley Fool Australia has recommended Cochlear. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Shot of a scientist using a computer while conducting research in a laboratory.
Broker Notes

Are Telix shares a buy, hold or sell following results?

This exciting healthcare stock is tipped to keep rising.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Up 53%, here's why this ASX All Ords healthcare share is tipped for more outperformance

A leading fund manager forecasts more outperformance from this surging ASX healthcare share.

Read more »

Six smiling health workers pose for a selfie.
Healthcare Shares

Up 79% since February, why are Telix shares jumping higher again on Tuesday?

Investors are piling into Telix shares in Tuesday’s slumping market. But why?

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

Top 3 ASX healthcare stocks to watch

Three beaten-down ASX healthcare stocks staging a strong comeback.

Read more »

A man in trendy clothing sits on a bench in a shopping mall looking at his phone with interest and a surprised look on his face.
Healthcare Shares

Telix Pharmaceuticals: Q2 2026 revenue jumps 21%

Telix Pharmaceuticals also provided an update on its key clinical pipeline and new partnerships.

Read more »

Stressed, unhappy, and tired scientist with a headache working on a computer in a lab.
Healthcare Shares

Down 50%+: Are these ASX healthcare shares finally worth buying?

Both healthcare leaders face setbacks, but their competitive advantages remain intact.

Read more »

Woman serving customer in pharmacy.
Healthcare Shares

Chemist Warehouse: Are Sigma Healthcare shares a buy, hold, or sell?

Bell Potter has been looking at the pharmacy giant following the release of a major report.

Read more »

Businessman working on street in New York.
Healthcare Shares

This ASX biotech stock just scored a Nasdaq listing. Shares are jumping

Investors seem excited about the biotech's global ambitions and growth plans.

Read more »